Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical
company, today launched Reroute Migraine Relief, an educational
initiative which aims to raise awareness of the complexities of
migraine, including the underrecognized connection between the
brain and gut. The new initiative, available on
reroutemigrainerelief.com, educates the public about the complex
nature of migraine, including the brain/gut connection, and
features unique illustrations from internationally renowned
portrait artist Ed Fairburn. The campaign also has a website for
healthcare providers, reroutemigrainereliefHCP.com.
Migraine affects approximately 36 million people in the U.S. and
is the second most common cause of disability.1,2 Migraine attacks
both the brain and the gut. Gastrointestinal (GI) symptoms related
to migraine include nausea, vomiting, and constipation, among
others. In fact, evidence shows 73 percent of patients with
migraine experience nausea and 29 percent experience vomiting.3
“Migraine is complex and evidence suggests it affects the entire
body, including the gut. GI symptoms can delay or reduce the
absorption of oral medications, leaving patients with incomplete or
inadequate relief from migraine symptoms,” said Lauren Natbony,
M.D., neurologist and headache specialist. “Given the prevalence of
GI symptoms in people with migraine, there is a need for a better
understanding of the connection between migraine and the gut.”
As one of the millions of people who has lived with migraine and
experienced related GI symptoms, Ed Fairburn knows first-hand just
how complex and debilitating migraine can be. Ed is known for his
skillful integration of portraiture and cartography. For his
artwork in Reroute Migraine Relief, Ed transforms the topography of
existing maps into portraits, underscoring the idea that similar to
winding and complicated streets, migraines can be hard to
navigate.
“My experience, and that of so many others who live with
migraine, has inspired the artwork I’ve developed for Reroute
Migraine Relief, and I’m excited to be able to bring the
complexities of migraine to life,” said Fairburn. “The maps I use
as the basis of my work reveal the complex inner workings of cities
and their twisting, turning roads. For many, that’s what life with
migraine entails – trying to navigate various symptoms and
treatment options, to determine the right path forward.”
A study published in the April 1, 2021 issue of Headache: The
Journal of Head and Face Pain found that GI disorders—including
gastroparesis (delayed gastric emptying), cyclic vomiting syndrome,
and irritable bowel syndrome, among others—are underrecognized
among people who have migraine.4 It’s important to understand this
connection to consider the best routes of administration for acute
migraine treatments. Impel NeuroPharma is exploring delivery of
medication to the upper nasal space, a vascular rich area and
potential optimal target for acute migraine treatment.
“Despite recent advances, some people with migraine may cycle
through different oral treatments because they are not getting
adequate relief,” said Sheena Aurora, M.D., Vice President of
Medical Affairs, Migraine Franchise at Impel NeuroPharma and lead
author of the Headache study. “We are proud to launch Reroute
Migraine Relief to educate healthcare providers and patients about
the connection between the gut and brain, the need for alternate
routes of administration, and the potential of the vascular-rich
upper nasal space for treatment delivery.”
To learn more about Reroute Migraine Relief, visit
reroutemigrainerelief.com. There is also a website dedicated
strictly to healthcare professionals,
reroutemigrainereliefHCP.com.
About Acute MigraineMigraine is
a common and debilitating neurological disease characterized by
recurrent episodes of severe head pain and associated with nausea,
vomiting and sensitivity to light and sound.5 Migraine affects
approximately 36 million people in the United States.1 While
triptans account for almost 80 percent of migraine therapies,
approximately 30 to 40 percent of patients do not respond
adequately to triptans and up to 79 percent of the patients who do
respond to triptans report being dissatisfied with their current
treatment and willing to try a new therapy.6,7,8 Further, evidence
suggests that gastroparesis, delayed emptying of the stomach, is a
prevalent feature in migraine that may delay or reduce the
absorption of oral medications, including triptans, gepants and
ditans. This means that acute medications can remain in the stomach
for hours, delaying symptom relief, leading to loss of confidence
(about future administration) and prolonged suffering for the
current migraine attack.9,10,11
About Impel NeuroPharmaImpel
NeuroPharma, Inc. is a late-stage pharmaceutical company focused on
utilizing its proprietary technology to develop and commercialize
transformative therapies for people suffering from diseases with
high unmet needs, with an initial focus on diseases of the CNS. The
Company’s strategy is to rapidly advance its product candidate
pipeline that pairs its proprietary Precision Olfactory Delivery
(POD®) system with well-established therapeutics, including INP104
for the acute treatment of migraine, INP105 for the acute treatment
of agitation and aggression in patients with autism, and INP107 for
OFF episodes in Parkinson’s disease.
Cautionary Note on Forward-Looking
StatementsThis press release contains "forward-looking"
statements within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995, including,
but not limited to, timing of approval of Impel’s NDA for INP104
and of Impel’s other regulatory submissions, timing of
announcements of clinical results and clinical development
activities of its product candidates, potential benefits and market
opportunities of INP104 and its other product candidates and its
cash runway. Forward-looking statements can be identified by words
such as: “believe,” “may,” “will,” “potentially,” “estimate,”
“continue,” “anticipate,” “intend,” “could,” “would,” “project,”
“plan,” “expect” or the negative or plural of these words or
similar expressions. These statements are subject to numerous risks
and uncertainties that could cause actual results and events to
differ materially from those anticipated, including but not limited
to, Impel’s ability to obtain and maintain regulatory approval of
INP104 and its other product candidates, its ability to execute its
commercialization strategy for INP104, its ability to develop,
manufacture and commercialize its product candidates including
plans for future development of its POD devices and plans to
address additional indications for which Impel may pursue
regulatory approval, whether results of preclinical studies or
clinical trials will be indicative of the results of future trials,
and the effects of COVID-19 on its clinical programs and business
operations. Many of these risks are described in greater detail in
Impel’s filings with the Securities and Exchange Commission. Any
forward-looking statements in this press release speak only as of
the date of this press release. Impel assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Impel, POD and the Impel logo are U.S. registered trademarks of
Impel NeuroPharma, Inc. To learn more about Impel NeuroPharma,
please visit our website at https://impelnp.com/.
Contact:Lance BuckleyLippe Taylor
Grouplbuckley@lippetaylor.com917-439-2241
- Borsook D, Dodick DW. Taking the headache out of
migraine. Neurol Clin Pract. 2015 Aug; 5(4): 317–325.
- Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains
second among the world’s causes of disability, and first among
young women: findings from GBD2019. J Headache Pain. 2020 Dec
2;21(1):137.
- Lipton RB, et al. Prevalence and burden of migraine in the
United States: data from the American Migraine Study II. Headache.
2001;41:646-657.
- Aurora S, et al. A link between gastrointestinal disorders and
migraine: Insights into the gut–brain connection. Headache. 2021
Apr;61(4):576-589. doi: 10.1111/head.14099. Epub 2021 Apr 1.
- Mayo Clinic. Migraine Symptoms & Causes. Last Accessed
February 3, 2020.
- Smitherman TA, Burch R, et al. The prevalence, impact, and
treatment of migraine and severe headaches in the United States: a
review of statistics from national surveillance studies. Headache.
2013 Mar;53(3):427-36.
- Leroux E, Buchanan A, et al. Evaluation of patients with
insufficient efficacy and/or tolerability to triptans for the acute
treatment of migraine: A systematic literature review. Adv Ther.
2020 Dec;37(12):4765-4796.
- Bigal M, Rapoport A, et al. Satisfaction with current migraine
therapy: experience from 3 centers in US and Sweden. Headache. 2007
Apr;47(4):475-9.
- Aurora S, et al. Gastric stasis in migraineurs: Etiology,
characteristics, and clinical and therapeutic implications.
Cephalalgia. 2013; 33:408-415
- Tokola RA et al. Effect of migraine attacks on paracetamol
absorption. Br J Clin Pharmacol. 1984. 18:867-871
- Volans GN. Migraine and drug
absorption. Clin Pharmacokinet. 1978. 3:313-318
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ac47c877-7a8f-4e7b-8a18-651c62afa08e
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Jul 2023 to Jul 2024